Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/12/22
End: 11/29/22
Due: 11/29/23
Phase: N/A
Priority: Normal
Start: 08/03/21
End: 01/05/22
Due: 01/05/23
Phase: N/A
Priority: Normal
Start: 02/02/24
End: 06/30/26
Due: 06/30/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Ascending Multiple Intravenous Doses of AON-D21 in Healthy Male Subjects. | NCT05343819 | Aptarion Biotech AG | user2@example.com | None | 2022-04-12 | 2022-11-29 | 2023-11-29 | - | - | 2025-07-14 |
| First-in-human Trial With Single-dose C5a-neutralizing AON-D21 in Healthy Male Subjects | NCT05018403 | Aptarion Biotech AG | user2@example.com | None | 2021-08-03 | 2022-01-05 | 2023-01-05 | - | - | 2025-07-14 |
| Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia. | NCT05962606 | Aptarion Biotech AG | user2@example.com | None | 2024-02-02 | 2026-06-30 | 2027-06-30 | - | - | 2025-07-14 |